1. Home
  2. HCM
  3. HCM News

Latest HUTCHMED (China) Limited (HCM) News on October 30, 2025

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
HCM

GlobeNewswire

a month ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
HCM

GlobeNewswire

2 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HCM

MT Newswires

4 months ago

Hutchmed New Drug Application for Lung Cancer Combination Treatment Approved in China

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
HCM

GlobeNewswire

4 months ago

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%
HCM

Zacks

4 months ago

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£231m last week
HCM

Simply Wall St.

4 months ago

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£231m last week

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HCM

GlobeNewswire

5 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
HCM

GlobeNewswire

5 months ago

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
HCM

GlobeNewswire

5 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
HCM

GlobeNewswire

5 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
HCM

GlobeNewswire

6 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
HCM

GlobeNewswire

6 months ago

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
HCM

GlobeNewswire

6 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
HCM

GlobeNewswire

6 months ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
HCM

GlobeNewswire

6 months ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
HCM

GlobeNewswire

7 months ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
HCM

Simply Wall St.

7 months ago

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
HCM

GlobeNewswire

7 months ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...
HCM

GuruFocus.com

7 months ago

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
HCM

GlobeNewswire

7 months ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HCM

GlobeNewswire

7 months ago

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
HCM

GlobeNewswire

7 months ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
HCM

Simply Wall St.

8 months ago

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
HCM

GlobeNewswire

8 months ago

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HCM

GlobeNewswire

8 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED to Announce 2024 Final Results
HCM

GlobeNewswire

8 months ago

HUTCHMED to Announce 2024 Final Results

Hutchmed price target raised to $27 from $26 at BofA
HCM

TipRanks

9 months ago

Hutchmed price target raised to $27 from $26 at BofA

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HCM

GlobeNewswire

10 months ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
HCM

Simply Wall St.

10 months ago

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

Hutchmed divests 45% interest in Shanghai Hutchison for $608M
HCM

TipRanks

10 months ago

Hutchmed divests 45% interest in Shanghai Hutchison for $608M

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
HCM

GlobeNewswire

10 months ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
HCM

GlobeNewswire

10 months ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
HCM

GlobeNewswire

a year ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
HCM

PR Newswire

a year ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
HCM

GlobeNewswire

a year ago

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
HCM

GlobeNewswire

a year ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
HCM

GlobeNewswire

a year ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
HCM

GuruFocus.com

a year ago

HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
HCM

Simply Wall St.

a year ago

HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
HCM

GlobeNewswire

a year ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

a year ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

a year ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
HCM

GlobeNewswire

a year ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
HCM

GlobeNewswire

a year ago

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
HCM

Insider Monkey

a year ago

HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
HCM

GlobeNewswire

a year ago

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HUTCHMED Reports 2024 Interim Results and Provides Business Updates
HCM

GlobeNewswire

a year ago

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
HCM

Simply Wall St.

a year ago

HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
HCM

GlobeNewswire

a year ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED to Announce 2024 Half-Year Financial Results
HCM

GlobeNewswire

a year ago

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
HCM

GlobeNewswire

a year ago

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HCM

GlobeNewswire

a year ago

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HCM

GlobeNewswire

a year ago

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HCM

GlobeNewswire

a year ago

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HCM

GlobeNewswire

a year ago

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
HCM

GlobeNewswire

a year ago

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HCM

GlobeNewswire

a year ago

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HCM

GlobeNewswire

a year ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
HCM

GlobeNewswire

2 years ago

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
HCM

Simply Wall St.

2 years ago

HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years

HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HCM

GlobeNewswire

2 years ago

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
HCM

GlobeNewswire

2 years ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
HCM

Simply Wall St.

2 years ago

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HCM

GlobeNewswire

2 years ago

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HCM

GlobeNewswire

2 years ago

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)
HCM

Simply Wall St.

2 years ago

HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
HCM

GlobeNewswire

2 years ago

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
HCM

GlobeNewswire

2 years ago

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HCM

GlobeNewswire

2 years ago

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

Revolution Medicines to Participate in Upcoming Investor Conferences
HCM

GlobeNewswire

2 years ago

Revolution Medicines to Participate in Upcoming Investor Conferences

HUTCHMED to Announce 2023 Final Results
HCM

GlobeNewswire

2 years ago

HUTCHMED to Announce 2023 Final Results

What to Expect From Meritage Homes' (MTH) Q4 Earnings?
HCM

Zacks

2 years ago

What to Expect From Meritage Homes' (MTH) Q4 Earnings?

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
HCM

GlobeNewswire

2 years ago

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Should You Hold Warrior Met Coal (HCC)?
HCM

Insider Monkey

2 years ago

Should You Hold Warrior Met Coal (HCC)?

WSFS Financial Corporation (NASDAQ:WSFS) Q4 2023 Earnings Call Transcript
HCM

Insider Monkey

2 years ago

WSFS Financial Corporation (NASDAQ:WSFS) Q4 2023 Earnings Call Transcript

Down 82%, 1 Warren Buffett Growth Stock to Buy in 2024
HCM

Motley Fool

2 years ago

Down 82%, 1 Warren Buffett Growth Stock to Buy in 2024

Forget Upstart Stock: 2 Stocks to Buy Hand Over Fist Instead
HCM

Motley Fool

2 years ago

Forget Upstart Stock: 2 Stocks to Buy Hand Over Fist Instead

Spire Declares Dividend
HCM

PR Newswire

2 years ago

Spire Declares Dividend

Virtu Financial (VIRT) Lags Q4 Earnings and Revenue Estimates
HCM

Zacks

2 years ago

Virtu Financial (VIRT) Lags Q4 Earnings and Revenue Estimates

Griffon (GFF) Beats Stock Market Upswing: What Investors Need to Know
HCM

Zacks

2 years ago

Griffon (GFF) Beats Stock Market Upswing: What Investors Need to Know

Stocks to Buy: 3 Sleeping Giants About to Wake Up and Soar
HCM

InvestorPlace

2 years ago

Stocks to Buy: 3 Sleeping Giants About to Wake Up and Soar

H.B. Fuller Announces Quarterly Dividend
HCM

Business Wire

2 years ago

H.B. Fuller Announces Quarterly Dividend

2 of the Best Stocks to Buy on a Dip in 2024
HCM

Motley Fool

2 years ago

2 of the Best Stocks to Buy on a Dip in 2024

Household Products Stocks Q3 Teardown: Church & Dwight (NYSE:CHD) Vs The Rest
HCM

StockStory

2 years ago

Household Products Stocks Q3 Teardown: Church & Dwight (NYSE:CHD) Vs The Rest

Celanese (CE) & Under Armour Partner to Develop Sustainable Fiber
HCM

Zacks

2 years ago

Celanese (CE) & Under Armour Partner to Develop Sustainable Fiber

Clearway Energy, Inc. to Report Fourth Quarter 2023 Financial Results on February 22, 2024
HCM

GlobeNewswire

2 years ago

Clearway Energy, Inc. to Report Fourth Quarter 2023 Financial Results on February 22, 2024

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider
HCM

Zacks

2 years ago

Axcelis Technologies (ACLS) Exceeds Market Returns: Some Facts to Consider

DigitalOcean's (DOCN) Expanding Portfolio Strengthens Prospect
HCM

Zacks

2 years ago

DigitalOcean's (DOCN) Expanding Portfolio Strengthens Prospect

Celanese and Under Armour Develop Innovative New NEOLAST™ Fiber for Use in Performance Stretch Fabrics
HCM

Business Wire

2 years ago

Celanese and Under Armour Develop Innovative New NEOLAST™ Fiber for Use in Performance Stretch Fabrics

HCM

Reuters

2 years ago

CORRECTED-SEC probes B. Riley deals with client tied to failed hedge fund - Bloomberg News

Share on Social Networks: